Abstract
The article presents the data of the analysis of modern data on the efficacy and safety of genetically engineered biological drugs registered in the Russian Federation for the treatment of moderately severe and severe forms of psoriasis. Thereview of modern domestic and foreign literature showed a higher efficacy and safety of biological preparations compared with basic anti-inflammatory therapy and the expediency of prescribing TNF-αinhibitors, IL-12/23, IL-17, IL-23 inhibitors in various forms of psoriasis, given the degree severity and comorbid conditions. This review will help practitioners to determine the most optimal treatment regimen for moderately severe and severe forms of psoriasis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
